All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer's shares rose 2.6% in early trading ... and that the opportunities for the pharmaceutical industry probably outweigh the risks. Judging by Kennedy's recent statements, Bourla said he ...

Global pharmaceutical company Pfizer (NYSE:PFE ... The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in research and ...